

Corrigendum

Clinical significance of Janus Kinase inhibitor selectivityErnest H. Choy¹

Rheumatology 2019;58:953–62.
doi:10.1093/rheumatology/key339

In Table 3, the entry in the 'DVT/PE' row, first column 'Tofacitinib (JAK, JAK3)' has been replaced with 'NR' as it states later in the paper that this is not reported.

¹CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK

Correspondence to: Ernest H. Choy, CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Tenovus Building, Heath Park, Cardiff CF14 4XN, UK.
E-mail: ChoyEH@cardiff.ac.uk